AngioDynamics, Inc. remains a volatile small-cap med-tech, with promising growth drivers but inconsistent execution and margin trajectory. ANGO's AlphaVac, Auryon, and NanoKnife are gaining traction, yet face entrenched competitors and unpredictable clinician adoption, especially for NanoKnife. Recent results showed strong Med Tech growth and margin improvement, but higher-than-expected operating expenses and NanoKnife volatility spooked investors.
AngioDynamics beats first-quarter earnings estimates as revenues rise 6.9% on strong Med Tech growth, with margin expansion and robust Auryon and NanoKnife sales.
AngioDynamics, Inc. (ANGO) Q1 2027 Earnings Call Transcript
| Electronic Equipment, Instruments & Components Industry | Information Technology Sector | James C. Clemmer CEO | XMUN Exchange | US03475V1017 ISIN |
| US Country | 632 Employees | - Last Dividend | - Last Split | 27 May 2004 IPO Date |
AngioDynamics, Inc. is a prominent provider of invasive medical devices, catering to the needs of professional healthcare providers across the United States and internationally. The company specializes in a broad spectrum of medical areas, including vascular access, surgery, peripheral vascular disease, and oncology. Established in 1988, AngioDynamics is committed to enhancing patient outcomes through its innovative technologies and solutions, headquartered in Latham, New York.